Endocrinol Metab.  2025 Feb;40(1):1-9. 10.3803/EnM.2024.2285.

Long-Term Prognosis and Systemic Impact of Acromegaly: Analyses Utilizing Korean National Health Insurance Data

• Hong S
• Han K
• Park CY

• KMID: 2565246
• DOI: http://doi.org/10.3803/EnM.2024.2285

Abstract

Acromegaly is a rare endocrine disorder caused by excessive growth hormone secretion. Its low prevalence poses challenges in studying its long-term prognosis and systemic effects. To address this research gap, we conducted five studies using nationwide cohort data from the Korean National Health Insurance Database (NHID). This review consolidates the findings of these studies, which examined various long-term effects of acromegaly. The results demonstrated significant associations between acromegaly and increased mortality, a higher prevalence of mortality, cardiovascular outcomes, neurodegenerative diseases, depression, end-stage kidney disease, respiratory complications, specifically bronchiectasis, spine & hip fracture, and malignancy. These findings highlight the critical need for early diagnosis, comprehensive care, and long-term monitoring, and underscore the importance of a multidisciplinary approach in managing acromegaly.

Keyword

Acromegaly; Atrial fibrillation; Bronchiectasis; Dementia; Depression; Kidney failure, chronic; Heart failure; Mortality; Parkinson disease

Figure

• 

  Fig. 1. Systemic effects of acromegaly based on studies using Korean National Health Insurance Data. IGF-1, insulin-like growth factor-1.

Reference

1. Colao A, Grasso LF, Giustina A, Melmed S, Chanson P, Pereira AM, et al. Acromegaly. Nat Rev Dis Primers. 2019; 5:20.

2. Kerbel J, Cano-Zaragoza A, Espinosa-Dorado R, Garcia de la Torre KE, Mercado M. Real world data on the epidemiology, diagnosis, and treatment of acromegaly: a registries-based approach. Arch Med Res. 2023; 54:102856.

3. Kim KJ, Kim EH, Kim JH, Roh E, Ahn CH, Rhee Y, et al. Endocrine rare diseases II fact sheet 2022. Seoul: Korean Endocrine Society;2022.

4. Park KH, Lee EJ, Seo GH, Ku CR. Risk for acromegaly-related comorbidities by sex in Korean acromegaly. J Clin Endocrinol Metab. 2020; 105:dgz317.

5. Song SO, Jung CH, Song YD, Park CY, Kwon HS, Cha BS, et al. Background and data configuration process of a nationwide population-based study using the Korean National Health Insurance System. Diabetes Metab J. 2014; 38:395–403.

6. Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol. 2008; 159:89–95.

7. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP. Mortality in acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2008; 93:61–7.

8. Mercado M, Gonzalez B, Vargas G, Ramirez C, de los Monteros AL, Sosa E, et al. Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. J Clin Endocrinol Metab. 2014; 99:4438–46.

9. Maione L, Brue T, Beckers A, Delemer B, Petrossians P, Borson-Chazot F, et al. Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry. Eur J Endocrinol. 2017; 176:645–55.

10. Arosio M, Reimondo G, Malchiodi E, Berchialla P, Borraccino A, De Marinis L, et al. Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol. 2012; 167:189–98.

11. Bogazzi F, Colao A, Rossi G, Lombardi M, Urbani C, Sardella C, et al. Comparison of the effects of primary somatostatin analogue therapy and pituitary adenomectomy on survival in patients with acromegaly: a retrospective cohort study. Eur J Endocrinol. 2013; 169:367–76.

12. Hong S, Kim KS, Han K, Park CY. Acromegaly and cardiovascular outcomes: a cohort study. Eur Heart J. 2022; 43:1491–9.

13. Bolfi F, Neves AF, Boguszewski CL, Nunes-Nogueira VS. Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis. Eur J Endocrinol. 2018; 179:59–71.

14. Kim J, Hong N, Choi J, Moon JH, Kim EH, Hong JW, et al. Sex differences in mortality in patients with acromegaly: a nationwide cohort study in Korea. Eur J Endocrinol. 2023; 189:225–34.

15. Sherlock M, Ayuk J, Tomlinson JW, Toogood AA, AragonAlonso A, Sheppard MC, et al. Mortality in patients with pituitary disease. Endocr Rev. 2010; 31:301–42.

16. Lie JT. Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients. Am Heart J. 1980; 100:41–52.

17. Colao A. The GH-IGF-I axis and the cardiovascular system: clinical implications. Clin Endocrinol (Oxf). 2008; 69:347–58.

18. Kahaly G, Olshausen KV, Mohr-Kahaly S, Erbel R, Boor S, Beyer J, et al. Arrhythmia profile in acromegaly. Eur Heart J. 1992; 13:51–6.

19. Mosca S, Paolillo S, Colao A, Bossone E, Cittadini A, Iudice FL, et al. Cardiovascular involvement in patients affected by acromegaly: an appraisal. Int J Cardiol. 2013; 167:1712–8.

20. Bihan H, Espinosa C, Valdes-Socin H, Salenave S, Young J, Levasseur S, et al. Long-term outcome of patients with acromegaly and congestive heart failure. J Clin Endocrinol Metab. 2004; 89:5308–13.

21. Schofl C, Petroff D, Tonjes A, Grussendorf M, Droste M, Stalla G, et al. Incidence of myocardial infarction and stroke in acromegaly patients: results from the German Acromegaly Registry. Pituitary. 2017; 20:635–42.

22. Dal J, Feldt-Rasmussen U, Andersen M, Kristensen LO, Laurberg P, Pedersen L, et al. Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study. Eur J Endocrinol. 2016; 175:181–90.

23. Colao A, Grasso LF, Di Somma C, Pivonello R. Acromegaly and heart failure. Heart Fail Clin. 2019; 15:399–408.

24. Brummelman P, Koerts J, Dullaart RP, van den Berg G, Tucha O, Wolffenbuttel BH, et al. Effects of previous growth hormone excess and current medical treatment for acromegaly on cognition. Eur J Clin Invest. 2012; 42:1317–24.

25. Crespo I, Santos A, Valassi E, Pires P, Webb SM, Resmini E. Impaired decision making and delayed memory are related with anxiety and depressive symptoms in acromegaly. Endocrine. 2015; 50:756–63.

26. Martin-Rodriguez JF, Madrazo-Atutxa A, Venegas-Moreno E, Benito-Lopez P, Galvez MA, Cano DA, et al. Neurocognitive function in acromegaly after surgical resection of GH-secreting adenoma versus naïve acromegaly. PLoS One. 2013; 8:e60041.

27. Godau J, Herfurth M, Kattner B, Gasser T, Berg D. Increased serum insulin-like growth factor 1 in early idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2010; 81:536–8.

28. Numao A, Suzuki K, Miyamoto M, Miyamoto T, Hirata K. Clinical correlates of serum insulin-like growth factor-1 in patients with Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. Parkinsonism Relat Disord. 2014; 20:212–6.

29. Picillo M, Erro R, Santangelo G, Pivonello R, Longo K, Pivonello C, et al. Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naive Parkinson’s disease. J Neurol. 2013; 260:1724–30.

30. Hong S, Han K, Kim KS, Park CY. Risk of neurodegenerative diseases in patients with acromegaly: a cohort study. Neurology. 2022; 99:e1875. –85.

31. Guo X, Wang K, Yu S, Gao L, Wang Z, Zhu H, et al. Quality of life and its determinants in patients with treated acromegaly: a cross-sectional nationwide study in China. J Clin Endocrinol Metab. 2021; 106:211–25.

32. Tiemensma J, Kaptein AA, Pereira AM, Smit JW, Romijn JA, Biermasz NR. Affected illness perceptions and the association with impaired quality of life in patients with long-term remission of acromegaly. J Clin Endocrinol Metab. 2011; 96:3550–8.

33. Sonino N, Ruini C, Navarrini C, Ottolini F, Sirri L, Paoletta A, et al. Psychosocial impairment in patients treated for pituitary disease: a controlled study. Clin Endocrinol (Oxf). 2007; 67:719–26.

34. Leon-Carrion J, Martin-Rodriguez JF, Madrazo-Atutxa A, Soto-Moreno A, Venegas-Moreno E, Torres-Vela E, et al. Evidence of cognitive and neurophysiological impairment in patients with untreated naive acromegaly. J Clin Endocrinol Metab. 2010; 95:4367–79.

35. Moon S, Hong S, Han K, Park CY. Risk of depression in patients with acromegaly in Korea (2006-2016): a nationwide population-based study. Eur J Endocrinol. 2023; 189:363–71.

36. Auriemma RS, Galdiero M, De Martino MC, De Leo M, Grasso LF, Vitale P, et al. The kidney in acromegaly: renal structure and function in patients with acromegaly during active disease and 1 year after disease remission. Eur J Endocrinol. 2010; 162:1035–42.

37. Fujio S, Takano K, Arimura H, Habu M, Bohara M, Hirano H, et al. Treatable glomerular hyperfiltration in patients with active acromegaly. Eur J Endocrinol. 2016; 175:325–33.

38. Hong S, Kim KS, Han K, Park CY. A cohort study found a high risk of end-stage kidney disease associated with acromegaly. Kidney Int. 2023; 104:820–7.

39. Cho J, Kim JH, Kim YH, Lee J. Obstructive sleep apnea screening and effects of surgery in acromegaly: a prospective study. Endocrinol Metab (Seoul). 2024; 39:641–52.

40. Camilo GB, Guimaraes FS, Silva DP, Mogami R, Kasuki L, Gadelha MR, et al. Pulmonary function testing and chest tomography in patients with acromegaly. Multidiscip Respir Med. 2013; 8:70.

41. Benfante A, Ciresi A, Bellia M, Cannizzaro F, Bellia V, Giordano C, et al. Early lung function abnormalities in acromegaly. Lung. 2015; 193:393–9.

42. Gil HI, Han K, Hong S, Park CY. Incidence of bronchiectasis in patients with acromegaly: a cohort study. Front Endocrinol (Lausanne). 2024; 15:1362950.

43. Giustina A. Acromegaly and bone: an update. Endocrinol Metab (Seoul). 2023; 38:655–66.

44. Mazziotti G, Bianchi A, Bonadonna S, Cimino V, Patelli I, Fusco A, et al. Prevalence of vertebral fractures in men with acromegaly. J Clin Endocrinol Metab. 2008; 93:4649–55.

45. Uygur MM, Yazici DD, Bugdayci O, Yavuz DG. Prevalence of vertebral fractures and serum sclerostin levels in acromegaly. Endocrine. 2021; 73:667–73.

46. Frara S, Melin Uygur M, di Filippo L, Doga M, Losa M, Santoro S, et al. High prevalence of vertebral fractures associated with preoperative GH levels in patients with recent diagnosis of acromegaly. J Clin Endocrinol Metab. 2022; 107:e2843. –50.

47. Mazziotti G, Bianchi A, Porcelli T, Mormando M, Maffezzoni F, Cristiano A, et al. Vertebral fractures in patients with acromegaly: a 3-year prospective study. J Clin Endocrinol Metab. 2013; 98:3402–10.

48. Kwon H, Han KD, Kim BS, Moon SJ, Park SE, Rhee EJ, et al. Acromegaly and the long-term fracture risk of the vertebra and hip: a national cohort study. Osteoporos Int. 2023; 34:1591–600.

49. Kim J, Hong N, Choi J, Moon JH, Kim EH, Lee EJ, et al. Increased risk of hip fracture in patients with acromegaly: a nationwide cohort study in Korea. Endocrinol Metab (Seoul). 2023; 38:690–700.

50. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004; 25:102–52.

51. Baris D, Gridley G, Ron E, Weiderpass E, Mellemkjaer L, Ekbom A, et al. Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes Control. 2002; 13:395–400.

52. Kauppinen-Makelin R, Sane T, Valimaki MJ, Markkanen H, Niskanen L, Ebeling T, et al. Increased cancer incidence in acromegaly: a nationwide survey. Clin Endocrinol (Oxf). 2010; 72:278–9.

53. Popovic V, Damjanovic S, Micic D, Nesovic M, Djurovic M, Petakov M, et al. Increased incidence of neoplasia in patients with pituitary adenomas. The Pituitary Study Group. Clin Endocrinol (Oxf). 1998; 49:441–5.

54. Ron E, Gridley G, Hrubec Z, Page W, Arora S, Fraumeni JF Jr. Acromegaly and gastrointestinal cancer. Cancer. 1991; 68:1673–7.

55. Barzilay J, Heatley GJ, Cushing GW. Benign and malignant tumors in patients with acromegaly. Arch Intern Med. 1991; 151:1629–32.

56. Petroff D, Tonjes A, Grussendorf M, Droste M, Dimopoulou C, Stalla G, et al. The incidence of cancer among acromegaly patients: results from the German Acromegaly Registry. J Clin Endocrinol Metab. 2015; 100:3894–902.

57. Mustacchi P, Shimkin MB. Occurrence of cancer in acromegaly and in hypopituitarism. Cancer. 1957; 10:100–4.

58. Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab. 1998; 83:2730–4.